JP2024540417A5 - - Google Patents

Info

Publication number
JP2024540417A5
JP2024540417A5 JP2024527216A JP2024527216A JP2024540417A5 JP 2024540417 A5 JP2024540417 A5 JP 2024540417A5 JP 2024527216 A JP2024527216 A JP 2024527216A JP 2024527216 A JP2024527216 A JP 2024527216A JP 2024540417 A5 JP2024540417 A5 JP 2024540417A5
Authority
JP
Japan
Application number
JP2024527216A
Other languages
Japanese (ja)
Other versions
JP2024540417A (ja
JPWO2023079177A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081155 external-priority patent/WO2023079177A1/en
Publication of JP2024540417A publication Critical patent/JP2024540417A/ja
Publication of JP2024540417A5 publication Critical patent/JP2024540417A5/ja
Publication of JPWO2023079177A5 publication Critical patent/JPWO2023079177A5/ja
Pending legal-status Critical Current

Links

JP2024527216A 2021-11-08 2022-11-08 ルルビネクテジン及びアテゾリズマブの組合せ Pending JP2024540417A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21383013 2021-11-08
EP21383013.6 2021-11-08
PCT/EP2022/081155 WO2023079177A1 (en) 2021-11-08 2022-11-08 Lurbinectedin and atezolizumab combinations

Publications (3)

Publication Number Publication Date
JP2024540417A JP2024540417A (ja) 2024-10-31
JP2024540417A5 true JP2024540417A5 (https=) 2025-11-18
JPWO2023079177A5 JPWO2023079177A5 (https=) 2025-11-18

Family

ID=78820304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527216A Pending JP2024540417A (ja) 2021-11-08 2022-11-08 ルルビネクテジン及びアテゾリズマブの組合せ

Country Status (9)

Country Link
US (1) US20240415834A1 (https=)
EP (1) EP4430075A1 (https=)
JP (1) JP2024540417A (https=)
KR (1) KR20240099455A (https=)
AU (1) AU2022381992A1 (https=)
CA (1) CA3237009A1 (https=)
IL (1) IL312263A (https=)
MX (1) MX2024005589A (https=)
WO (1) WO2023079177A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228594A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法

Similar Documents

Publication Publication Date Title
JP2024540417A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13151U (https=)
BY13135U (https=)
CN307049749S (https=)
BY13157U (https=)
BY13156U (https=)
BY13155U (https=)
BY13153U (https=)
BY13152U (https=)
BY13159U (https=)